Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage.
Theman
Todd A
TA
Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Hartzell
Tristan L
TL
Sinha
Indranil
I
Polson
Kathleen
K
Morgan
Jeffrey
J
Demetri
George D
GD
Orgill
Dennis P
DP
George
Suzanne
S
D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects; D002405:Catheterization, Central Venous / Q000009:adverse effects; D020878:Device Removal; D004149:Dioxoles / Q000008:administration & dosage / Q000009:adverse effects*; D004322:Drainage / Q000379:methods; D005119:Extravasation of Diagnostic and Therapeutic Materials; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D007262:Infusions, Intravenous; D007509:Irritants / Q000009:adverse effects*; D007890:Leiomyosarcoma / Q000188:drug therapy* / Q000473:pathology; D009336:Necrosis / Q000139:chemically induced / Q000473:pathology / Q000601:surgery; D012720:Severity of Illness Index; D012883:Skin Ulcer / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D017695:Soft Tissue Injuries / Q000139:chemically induced* / Q000503:physiopathology / Q000601:surgery; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage / Q000009:adverse effects*; D000077606:Trabectedin; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D004149:Dioxoles; D007509:Irritants; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin